| Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity HA Abbas, DR Maccio, S Coskun, JG Jackson, AL Hazen, TM Sills, ... Cell stem cell 7 (5), 606-617, 2010 | 153 | 2010 |
| Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates V Chitsazzadeh, C Coarfa, JA Drummond, T Nguyen, A Joseph, ... Nature communications 7 (1), 12601, 2016 | 134 | 2016 |
| A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia AGX Zeng, S Bansal, L Jin, A Mitchell, WC Chen, HA Abbas, ... Nature medicine 28 (6), 1212-1223, 2022 | 123 | 2022 |
| The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity V Pant, S Xiong, JG Jackson, SM Post, HA Abbas, A Quintás-Cardama, ... Genes & development 27 (17), 1857-1867, 2013 | 89 | 2013 |
| The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma M Zhuo, Y Guan, X Yang, L Hong, Y Wang, Z Li, R Chen, HA Abbas, ... Clinical Cancer Research 26 (4), 892-901, 2020 | 83 | 2020 |
| TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice S Jiang, LC Minter, SA Stratton, P Yang, HA Abbas, ZC Akdemir, V Pant, ... Journal of hepatology 62 (2), 371-379, 2015 | 72 | 2015 |
| Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment A Inati, MHA Noureldine, A Mansour, HA Abbas BioMed research international 2015, 2015 | 70 | 2015 |
| Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment A Inati, MHA Noureldine, A Mansour, HA Abbas BioMed research international 2015, 2015 | 70 | 2015 |
| Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Y Chu, E Dai, Y Li, G Han, G Pei, DR Ingram, K Thakkar, JJ Qin, M Dang, ... Nature medicine 29 (6), 1550-1562, 2023 | 65 | 2023 |
| Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML … N Daver, M Konopleva, A Maiti, TM Kadia, CD DiNardo, S Loghavi, ... Blood 138, 371, 2021 | 63 | 2021 |
| Association of Pre‐Pregnancy Body Mass Index and Gestational Weight Gain with Preterm Births and Fetal Size: an Observational Study from L ebanon R El Rafei, HA Abbas, L Charafeddine, P Nakad, A Al Bizri, D Hamod, ... Paediatric and perinatal epidemiology 30 (1), 38-45, 2016 | 57 | 2016 |
| Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy HA Abbas, D Hao, K Tomczak, P Barrodia, JS Im, PK Reville, Z Alaniz, ... Nature communications 12 (1), 6071, 2021 | 56 | 2021 |
| Azacitidine (AZA) with nivolumab (Nivo), and AZA with Nivo+ ipilimumab (Ipi) in relapsed/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study NG Daver, G Garcia-Manero, MY Konopleva, M Alfayez, N Pemmaraju, ... Blood 134, 830, 2019 | 52 | 2019 |
| TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway X Su, M Napoli, HA Abbas, A Venkatanarayan, NHB Bui, C Coarfa, YJ Gi, ... Oncogene 36 (17), 2377-2393, 2017 | 42 | 2017 |
| Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia … N Daver, J Senapati, A Maiti, S Loghavi, TM Kadia, CD DiNardo, ... Blood 140 (Supplement 1), 141-144, 2022 | 41 | 2022 |
| ΔNp63/DGCR8-dependent microRNAs mediate therapeutic efficacy of HDAC inhibitors in cancer M Napoli, A Venkatanarayan, P Raulji, BA Meyers, W Norton, LS Mangala, ... Cancer cell 29 (6), 874-888, 2016 | 41 | 2016 |
| Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection HA Abbas, M Alfayez, T Kadia, F Ravandi-Kashani, N Daver Cancer management and research, 8817-8828, 2019 | 35 | 2019 |
| The effect of consanguinity on neonatal outcomes and health HA Abbas, K Yunis Human heredity 77 (1-4), 87-92, 2014 | 34 | 2014 |
| Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia S Rutella, J Vadakekolathu, F Mazziotta, S Reeder, TO Yau, ... The Journal of Clinical Investigation 132 (21), 2022 | 33 | 2022 |
| Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies HA Abbas, WG Wierda Frontiers in Oncology 11, 668162, 2021 | 30 | 2021 |
